Results 11 to 20 of about 1,516,776 (324)

Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1

HIV Research & Clinical Practice, 2021
Background Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated in AMBER (treatment-naïve adults; NCT02431247) and EMERALD (treatment-experienced, virologically-suppressed adults; NCT02269917). Objective
Gregory D. Huhn, Aimee Wilkin, Cristina Mussini, Christoph D. Spinner, John Jezorwski, Mohsine El Ghazi, Erika Van Landuyt, Erkki Lathouwers, Kimberley Brown, Bryan Baugh, on behalf of the AMBER and EMERALD study groups   +10 more
doaj   +1 more source

Clinical prognostic factors for central neurocytoma and subgroup analysis of different treatment measures: A SEER database-based retrospective analysis from 2003 to 2019

Frontiers in Oncology, 2023
PurposeThe study aimed to identify clinical prognostic factors affecting overall survival (OS) in patients with central neurocytoma (CN) and to determine independent prognostic factors in the subgroups of different treatment modalities using a ...
Zibin Zhang, Jianbo Yu, Chao Zhang, Xiaojun Pang, Yuyu Wei, Qingping Lv, Huai Chen, Xuhong Jin, Renya Zhan   +8 more
doaj   +1 more source

Delivering diabetes education through nurseled telecoaching : cost-effectiveness analysis [PDF]

, 2016
Background : People with diabetes have a high risk of developing micro-and macrovascular complications associated with diminished life expectancy and elevated treatment costs. Patient education programs can improve diabetes control in the short term, but
Aertgeerts, Bert, Annemans, Lieven, Goderis, Geert, Nobels, Frank, Odnoletkova, Irina, Ramaekers, Dirk   +5 more
core   +6 more sources

model4you: An R Package for Personalised Treatment Effect Estimation

Journal of Open Research Software, 2019
Typical models estimating treatment effects assume that the treatment effect is the same for all individuals. Model-based recursive partitioning allows to relax this assumption and to estimate stratified treatment effects (model-based trees) or even ...
Heidi Seibold, Achim Zeileis, Torsten Hothorn   +2 more
doaj   +1 more source

Molecular subgroups of adult medulloblastoma: a long-term single-institution study [PDF]

, 2016
Background Recent transcriptomic approaches have demonstrated that there are at least 4 distinct subgroups in medulloblastoma (MB); however, survival studies of molecular subgroups in adult MB have been inconclusive because of small sample sizes. The aim
Ai, Lin, GIANGASPERO, FELICE, Li, Chunde, Li, Peng, Liu, Pinan, Luo, Lin, Ohgaki, Hiroko, Wang, Bo, Wang, Xingchao, Wang, Zhenmin, Xu, Lei, Yang, Zhijun, Zhang, Jing, Zhao, Fu   +13 more
core   +1 more source

Credibility of subgroup analyses by socioeconomic status in public health intervention evaluations:An underappreciated problem? [PDF]

, 2018
There is increasing interest amongst researchers and policy makers in identifying the effect of public health interventions on health inequalities by socioeconomic status (SES).
Archibald, Daryll, Doi, Lawrence, Frank, John, Inglis, Greig, Laird, Yvonne, Malden, Stephen, Marryat, Louise, McAteer, John, Pringle, Jan   +8 more
core   +3 more sources

Simple renal cyst as an independent risk factor for hypertension

The Journal of Clinical Hypertension, 2022
A simple renal cyst (SRC) may increase the risk for hypertension. The authors examined the relationship between a SRC and hypertension in participants receiving physical examinations at Hebei Medical University.
Yaqing Zhou, Limei Jia, Baojin Lu, Long Bai, Wei Cui   +4 more
doaj   +1 more source

Should research samples reflect the diversity of the population? [PDF]

, 2004
Recent research governance documents say that the body of research evidence must reflect population diversity. The response to this needs to be more sophisticated than simply ensuring minorities are present in samples.
Allmark, P. J.
core   +2 more sources

Cumulative subgroup analysis to reduce waste in clinical research for individualised medicine [PDF]

, 2016
Background: Although subgroup analyses in clinical trials may provide evidence for individualised medicine, their conduct and interpretation remain controversial.
AD Oxman, AD Oxman, AR Feinstein, AW Chan, AW Chan, BA Mulder, BEST, CAPRICORN, CIBIS-I, CIBIS-II, D Kotecha, DJ Veldhuisen van, F Waagstein, Fujian Song, G Simonneau, H Hemila, H Olschewski, HA Ghofrani, HD Zhang, HL Liu, J Lau, J Lau, J Sandoval, JA Joglar, JF Burke, LJ Rubin, M Packer, M Packer, M Rienstra, Max O. Bachmann, MD Flather, MERIT-HF, N Galie, N Galie, N Galie, P Alonso-Coello, P Lechat, P Ponikowski, PM Rothwell, PM Rothwell, R Varadhan, RD Riley, RJ Barst, RJ Barst, RL Rhee, RR Coeytaux, S Yusuf, SF Assmann, SG Thompson, SJ Pocock, T Pulido, X Sun, X Sun, X Sun, Y Huang   +54 more
core   +1 more source

Over-AVID subgroup analysis

Journal of the American College of Cardiology, 2001
Given the extensive time, effort and expense involved in performing large-scale clinical trials, there is a natural tendency to perform subgroup analyses on the accumulated data subsequent to termination of the trial. Assmann et al.
Goldberger, Jeffrey J., Parker, Michele A., Kadish, Alan H.   +2 more
openaire   +2 more sources